{
  "pmid": "22811580",
  "abstract": "Ras-driven transcriptome analysis identifies aurora kinase A as a potential  malignant peripheral nerve sheath tumor therapeutic target.  Patel AV(1), Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ,  Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.  Author information: (1)Divisions of Experimental Hematology and Cancer Biology, Oncology, and  Biomedical Informatics, Cincinnati Children's Hospital Medical Center,  Cincinnati, USA.  PURPOSE: Patients with neurofibromatosis type 1 (NF1) develop malignant  peripheral nerve sheath tumors (MPNST), which are often inoperable and do not  respond well to current chemotherapies or radiation. The goal of this study was  to use comprehensive gene expression analysis to identify novel therapeutic  targets. EXPERIMENTAL DESIGN: Nerve Schwann cells and/or their precursors are the  tumorigenic cell types in MPNST because of the loss of the NF1 gene, which  encodes the RasGAP protein neurofibromin. Therefore, we created a transgenic  mouse model, CNP-HRas12V, expressing constitutively active HRas in Schwann cells  and defined a Ras-induced gene expression signature to drive a Bayesian factor  regression model analysis of differentially expressed genes in mouse and human  neurofibromas and MPNSTs. We tested functional significance of Aurora kinase  overexpression in MPNST in vitro and in vivo using Aurora kinase short hairpin  RNAs (shRNA) and compounds that inhibit Aurora kinase. RESULTS: We identified 2,000 genes with probability of linkage to nerve Ras  signaling of which 339 were significantly differentially expressed in mouse and  human NF1-related tumor samples relative to normal nerves, including Aurora  kinase A (AURKA). AURKA was dramatically overexpressed and genomically amplified  in MPNSTs but not neurofibromas. Aurora kinase shRNAs and Aurora kinase  inhibitors blocked MPNST cell growth in vitro. Furthermore, an AURKA selective  inhibitor, MLN8237, stabilized tumor volume and significantly increased survival  of mice with MPNST xenografts. CONCLUSION: Integrative cross-species transcriptome analyses combined with  preclinical testing has provided an effective method for identifying candidates  for molecular-targeted therapeutics. Blocking Aurora kinases may be a viable  treatment platform for MPNST.  Â©2012 AACR.  DOI: 10.1158/1078-0432.CCR-12-1072 PMCID: PMC3902639 PMID: 22811580 [Indexed for MEDLINE]  Conflict of interest statement: Conflicts of Interest: None",
  "methods": "Experimental Design Nerve Schwann cells and/or their precursors are the tumorigenic cell types in MPNST due to the loss of the NF1 gene, which encodes the RasGAP protein neurofibromin. Therefore, we created a transgenic mouse model, CNP-HRas12V, expressing constitutively-active HRas in Schwann cells and defined a Ras-induced gene expression signature to drive a Bayesian factor regression model analysis of differentially expressed genes in mouse and human neurofibromas and MPNSTs. We tested functional significance of Aurora kinase over-expression in MPNST  in vitro  and  in vivo  using Aurora kinase shRNAs and compounds that inhibit Aurora kinase.",
  "introduction": "",
  "results": "Results We identified 2000 genes with probability of linkage to nerve Ras signaling of which 339 were significantly differentially expressed in mouse and human NF1-related tumor samples relative to normal nerves, including Aurora kinase A ( AURKA). AURKA  was dramatically over-expressed and genomically amplified in MPNSTs but not neurofibromas. Aurora kinase shRNAs and Aurora kinase inhibitors blocked MPNST cell growth  in vitro . Furthermore, an AURKA selective inhibitor, MLN8237, stabilized tumor volume and significantly increased survival of mice with MPNST xenografts.",
  "discussion": "Conclusion Integrative cross-species transcriptome analyses combined with preclinical testing has provided an effective method for identifying candidates for molecular-targeted therapeutics. Blocking Aurora kinases may be a viable treatment platform for MPNST.",
  "fetched_at": "2026-02-16T15:39:52.550413",
  "abstract_length": 2468,
  "methods_length": 654,
  "introduction_length": 0,
  "results_length": 578,
  "discussion_length": 260
}